Free, open source #thyroid risk stratification model for research. Anyone can create similar models without coding. Read our paper @EndoSocJournals link in comments @croendoyoung @Thyroid_ITS @TheEndoSociety @EndocrineToday @TIRO_expert @ETA_Thyroid @thyroid thyronaut.com/

Had a great time presenting at MID-ATLANTIC SOCIETY OF ENDOCRINOLOGISTS 2026 ANNUAL MEETING #EndoTwitter #AI #endocrinology

Smartphone photos show promise for predicting insulin resistance aaceendocrine.ai/videos/news…

Post GLP-1 weight gain - a potential solution? There is a vacuum in obesity care, and every clinician who prescribes these drugs sees it. #GLP-1 therapies work while patients take them. When treatment stops, whether for cost, side effects, supply, pregnancy plans, or personal choice, most patients regain a large share of the weight. Yet we have no approved therapy whose specific job is weight maintenance after a GLP-1 is stopped. The options today are limited: stay on the drug indefinitely, restart after regain occurs, rely on lifestyle support alone, or consider bariatric surgery in selected patients. That empty space is exactly where Fractyl is aiming Revita. Revita is a single endoscopic procedure that resurfaces the lining of the duodenum. The idea is to restore nutrient sensing and signaling that chronic metabolic disease disrupts, so the gut itself helps defend the lower weight after the drug is gone. No daily pills, no weekly injections, no implant. In the REMAIN-1 pivotal cohort, Revita met its six-month co-primary endpoint on weight regain compared with a sham procedure (p=0.0023). Fractyl is now focusing the whole company on it, with an FDA De Novo submission planned for late 2026, 12-month data expected in early 2027, and a possible US authorization in late 2027. The caveats matter. This is investigational in the United States, not FDA authorized. The results so far are company reported topline, not peer reviewed, and the headline release gives a p-value without the absolute difference in weight regain, which is the number clinicians actually need. Twelve-month durability is still unknown. If the full data hold up, Revita would be the first procedural option built specifically for the post-GLP-1 maintenance gap, alongside continued drug therapy and surgery, not a replacement for them. For now it is the clearest sign yet that the industry has noticed the vacuum: losing weight is no longer the only problem worth solving. Keeping it off after treatment stops is the next one. #obesity globenewswire.com/news-relea…

What if we treated high glucose not by giving a drug, but by removing glucose itself? A study in Science this week describes ECHO, an implantable device designed to do exactly that, without insulin and without medication. How it works: The implant sits under the skin and contains an electrocatalyst made of platinum decorated gold nanoclusters embedded in porous graphite. When wirelessly powered at low power (0.75 volts), the catalyst selectively converts blood glucose into gluconate. Gluconate carries less energy and is cleared by the kidneys into the urine, so both glucose and calories leave the body. Because the reaction is driven electrically, the rate of glucose removal is adjustable. Turn the current up, remove glucose faster. Turn it off, removal stops. The closed loop comes from pairing it with a standard continuous glucose monitor. The CGM detects glucose above a set threshold, the implant activates, glucose falls, and the system switches off. In this study it was also smartphone controlled. What happened in mice with type 2 diabetes and obesity: Glucose returned to the normal range within 1 hour of activation. Repeated treatment maintained control for 6 weeks with no detectable hypoglycemia. As glucose was removed, metabolism shifted toward fat use. Body weight and triglycerides fell, while free fatty acids and ketone bodies rose. No adverse physiological, inflammatory, or behavioral effects were detected over those 6 weeks. This is early stage, mice only, 6 weeks of data. Human questions are unanswered: catalyst durability over years, tissue reaction to a permanent implant, kidney handling of a sustained gluconate load, and whether the glucose removal rate scales from a mouse to a human. We already have effective human therapies with outcome data, from metformin and SGLT2 inhibitors to GLP-1 receptor agonists and automated insulin delivery. ECHO is not a replacement for any of them today. It is a proof of concept for a different category: closed loop diabetes care that does not deliver a drug at all, but removes the substrate itself. science.org/doi/10.1126/scie…

Does #menopause change how #obesity drugs work? CagriSema: 25% weight loss in women, graded by menopausal stage (The Menopause Society meeting, Oct 20). Novo reported two post hoc analyses of REDEFINE 1. In 2,309 women, weekly CagriSema 2.4 mg (cagrilintide + semaglutide) was associated with 25.0% mean weight loss at 68 weeks vs 3.0% placebo; the full-trial read was 22.7%, below Novo's 25% target. A second post hoc (1,902 women) showed a pre/peri/post gradient: 26.7%, 24.8%, 23.1%. CagriSema is investigational, not cleared by FDA yet.

Veligrotug, a Full IGF-1 Receptor Antagonist, Produces Rapid and Durable Improvement in Active Thyroid Eye Disease: The THRIVE Phase 3 Trial - Johnson Thomas, 2026 journals.sagepub.com/doi/ful…